| human | Q5 |
| P496 | ORCID iD | 0000-0001-8873-2545 |
| P1153 | Scopus author ID | 7005666365 |
| P735 | given name | Janet | Q13553631 |
| Janet | Q13553631 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q39847636 | A clinical study of gingivitis of deciduous and succadaneous permanent teeth in dogs |
| Q35995127 | A novel animal model for bone metastasis in human lung cancer. |
| Q53742346 | A vital microscopy study of the morphology of normal and inflamed gingiva. |
| Q39652453 | Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. |
| Q78756715 | Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure |
| Q40842049 | Anabolic effect of parathyroid hormone on cancellous and cortical bone histology. |
| Q45451865 | Analyzing spatial and temporal (222)Rn trends in Maine |
| Q36531514 | Application of fluorescence vital microscopy to the vasculature around erupting teeth |
| Q77734384 | Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat |
| Q71627868 | Autoradiographic study of the effect of 1,25-dihydroxyvitamin D3 on bone matrix synthesis in vitamin D replete rats |
| Q73815622 | Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34) |
| Q70160955 | Clinical study to compare the effect of stannous fluoride and chlorhexidine mouthrinses on plaque formation |
| Q66842903 | Gingival vasculature around erupting deciduous teeth of dogs and cats |
| Q71484676 | Growth hormone does not enhance the anabolic effect of human parathyroid hormone (1-34) on bone in aging multiparous and virgin rats |
| Q70288627 | Human parathyroid hormone (1-34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3 |
| Q54574990 | Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1. |
| Q28593384 | Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions |
| Q33343391 | IGF-I improved bone mineral density and body composition of weaver mutant mice |
| Q81739215 | Igf-I and postnatal growth of weaver mutant mice |
| Q73132759 | Immunohistochemical localization of selected early response genes expressed in trabecular bone of young rats given hPTH 1-34 |
| Q73289425 | In vivo comparison of activated protein-1 gene activation in response to human parathyroid hormone (hPTH)(1-34) and hPTH(1-84) in the distal femur metaphyses of young mice |
| Q70947260 | In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats |
| Q48443446 | Lawrence G. Raisz November 13, 1925-August 25, 2010. |
| Q69447189 | Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats |
| Q39692795 | MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. |
| Q36127420 | MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors |
| Q78077258 | Molecular characterization of gene expression changes in ROS 17/2.8 cells cultured in diffusion chambers in vivo |
| Q46981827 | Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormone |
| Q81603682 | Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning |
| Q34512283 | Novel interactions between FOXM1 and CDC25A regulate the cell cycle |
| Q41718185 | Nuclear matrix proteins and osteoblast gene expression. |
| Q44782936 | Osteoprogenitor cells as targets for ex vivo gene transfer. |
| Q42454959 | PTH-responsive osteoblast nuclear matrix architectural transcription factor binds to the rat type I collagen promoter. |
| Q73783534 | Parathyroid hormone (1-34)-mediated interleukin-6 induction |
| Q52177300 | Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. |
| Q71769566 | Parathyroid hormone regulates the expression of rat osteoblast and osteosarcoma nuclear matrix proteins |
| Q41049139 | Parathyroid hormone regulates the expression of the nuclear mitotic apparatus protein in the osteoblast-like cells, ROS 17/2.8. |
| Q35948130 | Periosteum: biology, regulation, and response to osteoporosis therapies. |
| Q72270519 | Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts |
| Q73063013 | Proliferating cells in the primary spongiosa express osteoblastic phenotype in vitro |
| Q84483785 | Proteomic characteristics of ex vivo-enriched adult human bone marrow mononuclear cells in continuous perfusion cultures |
| Q37622807 | Psychosocial adjustment of siblings of children with cancer: a systematic review |
| Q53624157 | RECQL4-deficient cells are hypersensitive to oxidative stress/damage: Insights for osteosarcoma prevalence and heterogeneity in Rothmund-Thomson syndrome. |
| Q71930650 | Rat osteoblast and osteosarcoma nuclear matrix proteins bind with sequence specificity to the rat type I collagen promoter |
| Q28509888 | Recql4 haploinsufficiency in mice leads to defects in osteoblast progenitors: Implications for low bone mass phenotype |
| Q74587775 | Recruitment and proliferative responses of osteoblasts after mechanical loading in vivo determined using sustained-release bromodeoxyuridine |
| Q34567570 | Serum proteome profiles identifies parathyroid hormone physiologic response. |
| Q51926007 | Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. |
| Q74302439 | Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment |
| Q33712675 | Stemming bone loss by suppressing apoptosis. |
| Q70279963 | Stimulation of undermineralized matrix formation by 1,25 dihydroxyvitamin D3 in long bones of rats |
| Q77730906 | The addition of a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats |
| Q28578885 | The expression of the nuclear matrix proteins NuMA, topoisomerase II-alpha, and -beta in bone and osseous cell culture: regulation by parathyroid hormone |
| Q68544037 | The organisation of the gingival vasculature |
| Q50918249 | Tissue matrix protein expression in human osteoblasts, osteosarcoma tumors, and osteosarcoma cell lines. |
| Q73448303 | Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis) |
| Q43006354 | Unmet challenges in cancer disparities--letter |
Search more.